Lucentis (ranibizumab) 10 mg/ml solution for injection – Novartis Pharmaceuticals UK Ltd – Revised SPC

Source: eMC (electronic Medicines Compendium)
Area: Other Library Updates > SPC Changes
Section 4.4 Special warnings and precautions for use has been updated to include the information that systemic adverse events including non-ocular haemorrhages and arterial thromboembolic events have been reported following intravitreal injection of VEGF inhibitors.   Please see link to the SPC for full prescribing information  

Full Story →